What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Richard Greil mainly focuses on Internal medicine, Oncology, Surgery, Breast cancer and Immunology.
Richard Greil combines topics linked to Gastroenterology with his work on Internal medicine.
His work carried out in the field of Oncology brings together such families of science as Trastuzumab, Phases of clinical research, Anastrozole, Capecitabine and Retrospective cohort study.
The Surgery study which covers Adverse effect that intersects with Clinical trial.
Richard Greil has researched Breast cancer in several fields, including Prospective cohort study, Gynecology and Chemotherapy regimen.
His Immunology research incorporates elements of Cytotoxic T cell and Cancer research.
His most cited work include:
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study (380 citations)
- Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial (293 citations)
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer (230 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Breast cancer, Surgery and Chemotherapy.
His Gastroenterology research extends to the thematically linked field of Internal medicine.
His work is dedicated to discovering how Oncology, Docetaxel are connected with Epirubicin and other disciplines.
His Breast cancer research includes themes of Zoledronic acid, Adjuvant, Hazard ratio and Endocrine system.
His Surgery research is multidisciplinary, incorporating perspectives in Dexamethasone and Rituximab.
Richard Greil combines subjects such as Thalidomide and Bortezomib with his study of Dexamethasone.
He most often published in these fields:
- Internal medicine (71.84%)
- Oncology (50.87%)
- Breast cancer (17.62%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (71.84%)
- Oncology (50.87%)
- Breast cancer (17.62%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Breast cancer, Cancer research and In patient.
Richard Greil regularly links together related areas like Gastroenterology in his Internal medicine studies.
Richard Greil interconnects Pembrolizumab, Pancreatic cancer, Metastatic breast cancer, First line and Gemcitabine in the investigation of issues within Oncology.
His Breast cancer research is multidisciplinary, incorporating elements of Colorectal cancer and Randomized controlled trial.
His Cancer research research is multidisciplinary, relying on both T cell, Leukemia, Chronic lymphocytic leukemia and Gene.
The concepts of his T cell study are interwoven with issues in Phase i study and Immune therapy.
Between 2018 and 2021, his most popular works were:
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study (380 citations)
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (196 citations)
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial (189 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Richard Greil focuses on Internal medicine, Oncology, Chemotherapy, Cancer research and In patient.
Many of his studies involve connections with topics such as Gastroenterology and Internal medicine.
His Oncology study integrates concerns from other disciplines, such as Pembrolizumab, Survival rate and Phases of clinical research.
His work deals with themes such as Stage, FOLFOX and Pancreatic ductal adenocarcinoma, which intersect with Chemotherapy.
His study in Cancer research is interdisciplinary in nature, drawing from both Exome sequencing, B-cell receptor, T cell, CD3 and Chronic lymphocytic leukemia.
His studies in Breast cancer integrate themes in fields like Liquid biopsy, Carcinoembryonic antigen, Oncogene and Toxicity.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
